Skip to main content

Peer Review reports

From: Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion–dependent anemia and thrombocytopenia

Original Submission
14 Apr 2015 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Author responded Author comments
Reviewed Reviewer Report
Reviewed Reviewer Report
Resubmission - Version 3
Submitted Manuscript version 3
Author responded Author comments
Reviewed Reviewer Report
Resubmission - Version 4
Submitted Manuscript version 4
Author responded Author comments
Reviewed Reviewer Report
Resubmission - Version 5
Submitted Manuscript version 5
Publishing
14 Apr 2016 Editorially accepted
3 May 2016 Article published 10.1186/s12878-016-0049-5

You can find further information about peer review here.

Back to article page

BMC Hematology

ISSN: 2052-1839

Contact us